Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 10 | 2020 | 1536 | 1.040 |
Why?
|
| Neurotoxins | 1 | 2015 | 30 | 0.510 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2015 | 37 | 0.510 |
Why?
|
| Paclitaxel | 1 | 2015 | 140 | 0.490 |
Why?
|
| Sphingolipids | 1 | 2015 | 337 | 0.410 |
Why?
|
| Amenorrhea | 1 | 2007 | 16 | 0.290 |
Why?
|
| Menopause, Premature | 1 | 2006 | 1 | 0.280 |
Why?
|
| Tamoxifen | 2 | 2018 | 62 | 0.270 |
Why?
|
| Osteoporosis | 1 | 2006 | 88 | 0.250 |
Why?
|
| Genes, BRCA2 | 1 | 2005 | 35 | 0.250 |
Why?
|
| Genes, BRCA1 | 1 | 2005 | 47 | 0.240 |
Why?
|
| Genetic Counseling | 1 | 2005 | 45 | 0.240 |
Why?
|
| Guideline Adherence | 1 | 2006 | 287 | 0.230 |
Why?
|
| Anticarcinogenic Agents | 1 | 2004 | 52 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 468 | 0.230 |
Why?
|
| Breast Feeding | 1 | 2005 | 159 | 0.220 |
Why?
|
| Receptors, Estrogen | 3 | 2020 | 142 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 772 | 0.190 |
Why?
|
| Cancer Survivors | 2 | 2020 | 146 | 0.180 |
Why?
|
| Exercise | 2 | 2020 | 658 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 1070 | 0.160 |
Why?
|
| Glycation End Products, Advanced | 1 | 2018 | 125 | 0.150 |
Why?
|
| Life Style | 1 | 2018 | 338 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2020 | 867 | 0.140 |
Why?
|
| Female | 10 | 2020 | 38074 | 0.120 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 1851 | 0.120 |
Why?
|
| HEK293 Cells | 1 | 2015 | 326 | 0.120 |
Why?
|
| Adult | 5 | 2015 | 21403 | 0.110 |
Why?
|
| Middle Aged | 6 | 2018 | 21147 | 0.100 |
Why?
|
| Pregnancy | 2 | 2007 | 2334 | 0.090 |
Why?
|
| Humans | 10 | 2020 | 68618 | 0.090 |
Why?
|
| Hot Flashes | 1 | 2009 | 8 | 0.080 |
Why?
|
| Sertraline | 1 | 2009 | 62 | 0.080 |
Why?
|
| Parity | 1 | 2007 | 71 | 0.070 |
Why?
|
| Taxoids | 1 | 2007 | 41 | 0.070 |
Why?
|
| Premenopause | 1 | 2007 | 57 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 129 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2006 | 20 | 0.070 |
Why?
|
| Calcium, Dietary | 1 | 2006 | 35 | 0.070 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2006 | 33 | 0.070 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2006 | 62 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 567 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2007 | 231 | 0.070 |
Why?
|
| Bone Density | 1 | 2006 | 159 | 0.060 |
Why?
|
| Sterilization, Tubal | 1 | 2005 | 5 | 0.060 |
Why?
|
| Ovariectomy | 1 | 2005 | 49 | 0.060 |
Why?
|
| Contraceptives, Oral | 1 | 2005 | 28 | 0.060 |
Why?
|
| Mastectomy | 1 | 2005 | 57 | 0.060 |
Why?
|
| Risk Factors | 3 | 2018 | 5731 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2004 | 17 | 0.060 |
Why?
|
| Hormones | 1 | 2004 | 42 | 0.060 |
Why?
|
| Texas | 1 | 2004 | 92 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 955 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 129 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2004 | 86 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2006 | 403 | 0.060 |
Why?
|
| Prognosis | 2 | 2006 | 2093 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 267 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 151 | 0.050 |
Why?
|
| Adolescent | 1 | 2015 | 8912 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2006 | 371 | 0.050 |
Why?
|
| Decision Making | 1 | 2005 | 410 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 800 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 511 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 931 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2800 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 111 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 99 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2004 | 2007 | 0.040 |
Why?
|
| Obesity | 1 | 2004 | 1076 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 332 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2007 | 7277 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 2689 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7029 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2006 | 57 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2006 | 129 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 1738 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2006 | 239 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 446 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 1056 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 947 | 0.010 |
Why?
|
| Aged | 1 | 2018 | 14862 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 508 | 0.010 |
Why?
|
| Incidence | 1 | 2006 | 1603 | 0.010 |
Why?
|
| Quality of Life | 1 | 2009 | 1515 | 0.010 |
Why?
|